ArticleFrontiers in genetics2012
Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine.
Article in Frontiers in genetics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 90 citations in OpenAlex.
- A Semi-Mechanistic Population Pharmacokinetic Model of Noscapine in Healthy Subjects Considering Hepatic First-Pass Extraction and CYP2C9 Genotypes.Drugs in R&D · 2024Trial
- Effect of Routine Cytochrome P450 2D6 and 2C19 Genotyping on Antipsychotic Drug Persistence in Patients With Schizophrenia: A Randomized Clinical Trial.JAMA network open · 2020Trial
- Progressing Preemptive Genotyping of CYP2C19 Allelic Variants for Sickle Cell Disease Patients.Genetic testing and molecular biomarkers · 2016Trial
- Genetic variants ofJournal of Taibah University Medical Sciences · 2026Article
- Role of pharmacogenomics for prevention of hypersensitivity reactions induced by aromatic antiseizure medications.Frontiers in pharmacology · 2025Review
- Evaluation of the Lipophilicity of Angularly Condensed Diquino- and Quinonaphthothiazines as Potential Candidates for New Drugs.Molecules (Basel, Switzerland) · 2024Article
- Allele and genotype frequencies of variants in P450 cytochromes, transports, and DNA repair enzymes in the Dominican Republic population.Frontiers in pharmacology · 2024Article
- From genes to drugs:Frontiers in pharmacology · 2024Review
- The Diversity ofThe application of clinical genetics · 2024Article
- Fungistatic Effect of Phthalide Lactones onMolecules (Basel, Switzerland) · 2023Article
- Epigenetic Mechanisms Contribute to Intraindividual Variations of Drug Metabolism Mediated by Cytochrome P450 Enzymes.Drug metabolism and disposition: the biological fate of chemicals · 2023Review
- Cannabis Pharmacogenomics: A Path to Personalized Medicine.Current issues in molecular biology · 2023Review
- Antimicrobial analysis of honey against Staphylococcus aureus isolates from wound, ADMET properties of its bioactive compounds and in-silico evaluation against dihydropteroate synthase.BMC complementary medicine and therapies · 2023Article
- Pharmacogenetics of P2YPharmacotherapy · 2023Review
- Pharmacogenomic profile of a central European urban random population-Czech population.PloS one · 2023Observational
- ComprehensiveFrontiers in pharmacology · 2023Article
- CYP2D6 and CYP2C19 Genes Associated with Tricontinental and Latin American Ancestry of Pe-ruviansDrug metabolism and bioanalysis letters · 2023Article
- Effects of Enzyme Induction and Polymorphism on the Pharmacokinetics of Isoniazid and Rifampin in Tuberculosis/HIV Patients.Antimicrobial agents and chemotherapy · 2022Article
- Effect of major CYP2C19 genetic polymorphisms onBiomedical reports · 2022Article
- Variants *1, *2, *3 and *17 of CYP2C19 Cytochrome among Helicobacter Pylori Carriers from Manaus, Amazonas State, Brazil.Asian Pacific journal of cancer prevention : APJCP · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
More than 30 years of genetic research on the CYP2C19 gene alone has identified approximately 2,000 reference single nucleotide polymorphisms (rsSNPs) containing 28 registered alleles in the P450 Allele Nomenclature Committee and the number continues to increase. However, knowledge of CYP2C19 SNPs remains limited with respect to biological functions. Functional information on the variant is essential for justifying its clinical use. Only common variants (minor allele frequency >5%) that represent CYP2C19*2, *3, *17, and others have been mostly studied. Discovery of new genetic variants is outstripping the generation of knowledge on the biological meanings of existing variants. Alternative strategies may be needed to fill this gap. The present study summarizes up-to-date knowledge on functional CYP2C19 variants discovered in phenotyped humans studied at the molecular level in vitro. Understanding the functional meanings of CYP2C19 variants is an essential step toward shifting the current medical paradigm to highly personalized therapeutic regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.